# 6-week Safety and PD Study in Adults With NAFLD

> **NCT03256526** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 53 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-06835919 Low Dose
- **DRUG:** PF-06835919 High Dose

## Key facts

- **NCT ID:** NCT03256526
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-27
- **Primary completion:** 2018-03-30
- **Final completion:** 2018-04-27
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2019-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03256526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03256526, "6-week Safety and PD Study in Adults With NAFLD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03256526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*